2003 Fiscal Year Final Research Report Summary
Basic research of annexin V as a molecular target therapy for gynecologic cancer
| Project/Area Number |
14571536
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | AKITA UNIVERSITY |
|---|
Principal Investigator |
SATO Hirokazu Akita University, School of Medicine, RESEARCH ASSOCIATE, 医学部, 助手 (60272035)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Toshinobu Akita University, School of Medicine, PROFESSOR, 医学部, 教授 (40002216)
SHIMIZU Yasushi Akita University, School of Medicine, RESEARCH ASSOCIATE, 医学部, 助手 (40333926)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Keywords | ANNEXIN V / PROTEIN KINASE C / SUPERINDUCTION |
|---|
| Research Abstract |
Recently, molecular mechanism of proliferation and progression of carcinoma cells (infiltration and invasion) has been well understood. As a result, molecular target therapy of cancer patient is developing in Europe and the United States. Clinical trials of some tyrosine kinase inhibitors have already carried out as anti -cancer drugs. Although protein kinase C (PKC) representing Ser/Thr protein kinases is one of the most important kinases, no endogenous inhibitor in the cell has not been discovered. We first separated and purified annexin V from human placenta, which was a Ca^<2+>-dependent phospholipid binding protein, and reported to inhibite protein kinase C activity in vitro. The purpose of this study is to elucidate the role of annexin V in the cell and to clarify whether annexin V can inhibit tumor progression in the cell, followed by developing molecular target therapy of cancer patients with Ser/Thr protein kinase inhibitors by inhibiting tumor progression.
We constructed annex
… More
in V-stably expressing human leukemia cell lines (HL-60). Although annexin V overexpression did not induce morphological changes in the cell lines, TPA-induced PKC activation was inhibited in annexin V overexpressing cells. We showed that PKCδ was a most likely, candidate of TPA targeting PKC isoforms that was inhibited by annexin V. Since annexin V overexpress ion did not induce phenotype, we approached biological function of annexin V by the elucidation of annexin V gene regulation. Our results suggest that (i)protein synthesis inhibitors (CHX, ANI) superinduce annexin V mRNA expression. (ii)TPA enhances CHX-induced the superinduction of annexin V mRNA in MCAS cells by activating PKC and mRNA transcription. (iii)ANI superinduces annexin V mRNA expression through the ERK1/2 MAPK pathway, but not through the p38 MAPK pathway. Taken together, these results indicated that the regulation of annexin V gene expression was negatively controlled at the transcription factor level, and that PKC and ERK1/2 pathway was involved in the induction of annexin V gene expression. Less
|
